Shay Capital’s TScan Therapeutics TCRX Stock Holding History

Shay Capital’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-21,363	Closed	-$64.9K	–	413
2024 Q4	$64.9K	Buy	+21,363	New	+$96.8K	0.01%	287

Other funds holding TCRX

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Checkpoint Capital San Francisco, California $279M AUM 45.74% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Shay Capital's TCRX Position: Q1 2025 in Review

Shay Capital sold out of TScan Therapeutics (TCRX) in Q1 2025, closing a stake of 21,363 shares — an estimated $64.9K sold.

Shay Capital first reported a position in TCRX in Q4 2024 and held it in 1 quarter. The position peaked at $64.9K in Q4 2024. 92 funds tracked by Wall St. Rank hold TCRX as of Q1 2025.

Shay Capital reported no remaining TScan Therapeutics position as of Q1 2025 after selling out during the quarter.
Shay Capital sold 21,363 TScan Therapeutics shares in Q1 2025, an estimated $64.9K.
Shay Capital first reported a position in TScan Therapeutics in Q4 2024 and held it in 1 quarter.
Shay Capital's TScan Therapeutics position peaked at $64.9K in Q4 2024.
92 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2025.

Based on Shay Capital's 13F filing for Q1 2025, filed 15 May 2025.